NP与MVP方案治疗非小细胞肺癌的临床观察

Clinical observation of NP and MVP combined chemotherapy for treating advanced non-small cell lung carcinoma.

目的 :观察诺维本 (NVB) +顺铂 (DDP) (NP方案 )与丝裂霉素 (MMC)、西艾克 (VDS)加顺铂 (MVP方案 )治疗晚期非小细胞肺癌(NSCLC)的临床疗效和不良反应。方法 :采用NP与MVP两方案分别治疗晚期NSCLC32例。结果 :NP组总有效为43 8 % ,中位生存期7 7个月 ,MVP组总有效34 4% ,中位生存期9 6个月 ,NP方案优于MVP方案 ,但差异无显著性 (P>0 05) ,两组剂量限制毒性均为骨髓抑制。结论 :NP与INP方案是治疗晚期NSCLC的有效方案 ,经积极处理不良反应可以耐受。

Objective:To observe the therapeutic effect and toxic side-effects of the combined chemotherapy with navelbine and cisplatin(NP regimen) and with micomycin plus vindesine and cisplatin(MVP regimen) in the treatment of advanced non-small cell lung carcinoma.Methods:Thirty-two patients received NP combied chemotherapy and thirty-two patients reveived MVP combied chemotherapy.Results:The overall response rate was 43.8% in the NP group and 34.4% in the MVP group.The median survival period was 7.7 months and 9.6 months respectively.NP regimen is better than MVP regimen in efficacy,but not dramatically different.Conclusion:This study shows that NP and MVP are active and tolerable regimens for trealment of advanced non-small cell lung carcinoma.